EW Healthcare Partners has signed a definitive merger agreement for the acquisition of all outstanding shares of women’s healthcare firm TherapeuticsMD common stock for a total enterprise value of nearly $177m.
EW Healthcare will acquire TherapeuticsMD through an affiliate for $10 per share in an all-cash transaction, followed by a merger.
TherapeuticsMD focuses on the development and marketing of new products for women.
Its products are designed with a therapeutic focus on family planning, reproductive health, and menopause management.
TherapeuticsMD CEO Hugh O’Dowd said: “We are very pleased to enter into this agreement with EW Healthcare Partners.
“Together, we will continue empowering women of all ages through a therapeutic focus in family planning, reproductive health, and menopause management.”
The company’s board of directors unanimously approved the transaction.
Subject to necessary conditions, the business combination is anticipated to conclude on or before 13 July this year.
Upon the closing of the deal, TherapeuticsMD will become a privately held company.
Greenhill is acting as the financial advisor for TherapeuticsMD while DLA Piper is the legal counsel. Kirkland & Ellis, and BCG are acting as advisors for EW Healthcare.
EW Healthcare Partners managing director Evis Hursever said: “EW Healthcare Partners has already made a significant investment in women’s health through its acquisition of Majorelle.
“TherapeuticsMD represents a unique opportunity for Majorelle to enter the US market and is a perfect fit with our ambitious plans to create a fast-growing, premier, trans-Atlantic women’s health platform.”
The healthcare investment firm has invested in more than 150 healthcare firms in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the US and Europe.